A government rule limiting access to Alzheimer’s drugs means most patients who would want newly approved Leqembi won’t be able to get it—unless the Medicare agency rewrites the rule
newly approved Alzheimer’sThe Food and Drug Administration on Friday approved Eisai Co. and Biogen Inc.’s Leqembi, known generically as lecanemab,
for the treatment of people with early-stage Alzheimer’s disease, the vast majority of whom are insured by Medicare. However, for the drug unless patients are enrolled in government-sanctioned clinical trials, and no such studies are ongoing or planned.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA approves Leqembi, Alzheimer's drug that modestly slows diseaseALZHEIMER'S DRUG: The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease's underlying biology. MORE:
Les mer »
Second Alzheimer’s treatment showing modest benefits for patients approved by FDAThe FDA has granted accelerated approval to a second Alzheimer’s drug that trial data show offers modest benefits to patients.
Les mer »
US approves breakthrough drug Leqembi to treat Alzheimer'sLeqembi and Aduhelm, which were jointly developed by Japan's Eisai and Biogen of US 'represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease,' says Food and Drug Administration.
Les mer »
Alzheimer’s drug that modestly slows disease OK’d by FDAThe drug, Leqembi, has been shown to slow the decline in memory and thinking that defines Alzheimer’s. But there are risks, including the need for infusions and the possibility of brain swelling.
Les mer »
Alzheimer’s Disease Treatments: What to Know About New and Future DrugsThe FDA approved a promising new drug to slow down Alzheimer’s disease. Here’s what to know about who will be eligible for the drug and how to pay for it.
Les mer »